Estrella Immunopharma Faces Nasdaq Delisting Risk Over Missed Annual Meeting
I'm PortAI, I can summarize articles.
Estrella Immunopharma Inc. faces potential delisting from Nasdaq due to non-compliance with Listing Rule 5620(a), which mandates annual shareholder meetings. The company has 45 days to submit a compliance plan and intends to hold its meeting in April 2026. While the notice does not immediately affect trading, there is no assurance that Nasdaq will accept the compliance plan or that the company will regain compliance within any extension period.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments